# Cyclacel Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyclacel-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Berkeley Heights, US
- Website: www.cyclacel.com
- Total disclosed funding: $87M
- Latest round: Series D (Jan 29, 2004)
- Investors on record: 24

## About

Founded in 1992 and based in New Jersey, US, Cyclacel Pharmaceuticals, Inc. develops oral therapies and small molecule cycle inhibitors to target the various phases of cell cycle control for the treatment of cancer and other serious diseases.

## Funding rounds

- Series D, Jan 29, 2004, $39M — Invesco, Quester Capital Management, Scottish Equity Partners, Temasek Holdings, HBM Partners, Excalibur Fund Managers, SGAM Private Equity, Daiwa Corporate Investment, Merifin Capital, UOB Venture Management, GeneChem, LDC, Quest Management, Carnegie Investment Bank AB, D.C. Thomson & Co. Ltd., Noble Grossart, Biomedical Sciences Investment Fund, BankInvest, Finsbury Life Sciences Investment Trust, Northern Ventures
- Series C, Jun 4, 2001, $48M — OMTI, Invesco, Quester Capital Management, Scottish Equity Partners, Merifin Capital, GeneChem, LDC, SG Growth Capital, Noble Grossart, BankInvest, Finsbury Life Sciences Investment Trust, Northern Ventures, Merlin Biosciences Fund Ltd, Vertex Holdings

## Investors

- OMTI — Series C
- Invesco (https://capitalatlas.ai/funds/invesco) — Series C, Series D
- Quester Capital Management (https://capitalatlas.ai/funds/quester-capital-management) — Series C, Series D
- Scottish Equity Partners (https://capitalatlas.ai/funds/scottish-equity-partners) — Series C, Series D
- Merifin Capital (https://capitalatlas.ai/funds/merifin-capital) — Series C, Series D
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series C, Series D
- LDC (https://capitalatlas.ai/funds/ldc) — Series C, Series D
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C
- Noble Grossart — Series C, Series D
- BankInvest (https://capitalatlas.ai/funds/bankinvest) — Series C, Series D
- Finsbury Life Sciences Investment Trust — Series C, Series D
- Northern Ventures — Series C, Series D
- Merlin Biosciences Fund Ltd — Series C
- Vertex Holdings (https://capitalatlas.ai/funds/vertex-holdings) — Series C
- Temasek Holdings — Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Excalibur Fund Managers (https://capitalatlas.ai/funds/excalibur-fund-managers) — Series D
- SGAM Private Equity (https://capitalatlas.ai/funds/sgam-private-equity) — Series D
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series D
- UOB Venture Management (https://capitalatlas.ai/funds/uob-venture-management) — Series D
- Quest Management (https://capitalatlas.ai/funds/quest-management) — Series D
- Carnegie Investment Bank AB — Series D
- D.C. Thomson & Co. Ltd. — Series D
- Biomedical Sciences Investment Fund — Series D